Lyra’s SRS solution has drawn a lot of attention during the recent IUGA 2015 annual meeting.
Kerem-Maharal, Israel, June 12th, 2015 – Prof. Mauro Cervigni, one of the world’s most prominent Urogynecologists and a Pelvic Reconstructive Surgery expert presented a video presentation with Lyra Medical’s SRS technology surgical procedure.
This innovative concept drew a lot of attention from the large audience who attended Prof. Cervigni’s presentation. The audience appreciated the simplicity of the procedure as well as the promising interim clinical results and safety evaluation.
“SRS technology provides the ultimate implant for the treatment of anterior wall vaginal prolapse. The ease of use and the impressive anatomical and subjective outcomes are far superior to any other mesh implants ever used. I am confident that SRS-based solutions will revolutionize the treatment of prolapse, the same way that TVT did to treating incontinence. I have no doubt that SRS will become the next gold standard for reconstructive pelvic surgery,” said Prof. Mauro Cervigni, Head of Female Pelvic Medicine & Reconstructive Surgery, University Hospital Foundation A. Gemelli Catholic University, Rome, Italy.
“The great interest that Prof. Cervigni’s presentation drew is yet another demonstration of the acute need for therapeutic solutions that deliver both safety and long-term efficacy. Unfortunately, current solutions were shown to provide either safety or efficacy but not both,” added Iram Levit, Lyra Medical’s CEO.
The video which was presented during Prof. Cervigni’s presentation is available on Lyra’s website Resourcesà Videos & Animation page.
About Lyra Medical
Lyra Medical was established in 2011 by a team of seasoned medical device entrepreneurs to develop a new and safer organ support implant for women suffering from pelvic organ prolapse (POP).
The company’s Self-Retaining Support (SRS) technology is presently being applied in the flagship Lyra system for anterior vaginal wall, Apex and uterine prolapse. The support platform may be applicable in other pelvic organ disorder conditions, such as rectocele and urinary incontinence, as well as other clinical areas. In all these areas, there is an acute need for therapeutic solutions that deliver exceptional safety and long-term efficacy.